/
BMRN
$67.36-$1.17 (-1.71%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$13.6B
194M shares
52-week range
$49.26 – $70.98
83% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-7.74
BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
www.biomarin.com- Employees
- 3,221
- IPO / List date
- Jul 23, 1999
- HQ
- NOVATO, CA
Held by traders on TradeandTell
No one on the platform currently holds BMRN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,024,871 | $57.9M |
| Bridgewater Associatesas of 2026-03-31 | 206,911 | $11.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BMRN yet.
